MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)

BIOLOGICAL2 trials

Sponsors

Seqirus

Conditions

InfluenzaInfluenza, Human

Phase 3

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

CompletedNCT02587221

SeqirusInfluenza

Start: 2016-09-30End: 2018-07-23Updated: 2020-06-17

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

CompletedNCT03314662

SeqirusInfluenza, Human

Start: 2017-10-17End: 2018-05-17Updated: 2020-07-22

Related Papers

Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study.

2021-02-0938 citations

Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults

Vaccine2019-10-1843 citations